MTOR and acute lymphoblastic leukemia: In conclusion, our results demonstrated that targeting PI3K/Akt/mTOR pathway at different levels in T-ALL cell lines resulted in an increase of cytotoxic effects and then at least some of tested inhibitors may represent promising drugs also for their capacity to target T-ALL LICs.